Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants [0.03%]
健康成人参与者中TLR7激动剂JNJ-64794964的群体药代动力学/药效学模型
Liviawati S Wu,Yue Hu,Edward J Gane et al.
Liviawati S Wu et al.
Background: JNJ-4964 is a TLR7 agonist, which, via a type I interferon (IFN)-dependent mechanism, may enhance host immunity suppressed by persistent exposure to hepatitis B antigens in chronic hepatitis B. ...
Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration [0.03%]
正在接受连续性静脉-静脉血液滤过治疗的危重患者的扎那米韦药代动力学特征研究
André Wieringa,Peter Gj Ter Horst,GertJan Hj Wagenvoort et al.
André Wieringa et al.
Background: Limited data exist for dosing of zanamivir in the setting of CVVH in the intensive care unit (ICU). Our objective is to report the pharmacokinetics and sieving coefficient (Sv) of zanamivir in patients receivi...
Observational Study
Antiviral therapy. 2023 Feb;28(1):13596535221150746. DOI:10.1177/13596535221150746 2023
A favipiravir-induced angioedema and urticaria in a COVID-19 patient [0.03%]
COVID-19患者中由法维拉韦引起的血管性水肿和荨麻疹
Figen Ergur Ozturk,Ayperi Ozturk,Hale Ates
Figen Ergur Ozturk
Although favipiravir is a promising drug for coronavirus disease 2019, some adverse effects, including skin lesions, have been reported. A 56-year-old female who was prescribed favipiravir by a filiation team following a positive severe acu...
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C [0.03%]
直接抗病毒治疗对慢性丙型肝炎患者体重的影响的理解
Chinyere L Nkwocha,Pamela S Carter,Somer Blair et al.
Chinyere L Nkwocha et al.
Background: Direct-acting antivirals (DAAs) have revolutionized treatment for HCV. Compared to interferon-based therapies, DAAs achieve higher rates of sustained virologic response, with more tolerable side effects. Nonet...
Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients [0.03%]
利特莫维r用于治疗两名心脏移植受者的复杂巨细胞病毒再激活问题
Aude Boignard,Caroline Augier,Mathilde Kheng et al.
Aude Boignard et al.
Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of lete...
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B [0.03%]
EDP-514在健康受试者和核苷（t）酸逆转录酶抑制剂抑制的慢性乙型肝炎患者中的应用
Jordan J Feld,Eric Lawitz,Tuan Nguyen et al.
Jordan J Feld et al.
Background: Chronic hepatitis B (CHB) remains a major cause of morbidity and mortality. EDP-514 is a potent core inhibitor of hepatitis B virus (HBV) that reduces viral load reduction in HBV-infected chimeric mice. This f...
Stephen Locarnini,Douglas Richman,Richard Whitley
Stephen Locarnini
Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case-control study from Uganda and South Africa [0.03%]
抗逆转录病毒治疗依从性模式、病毒抑制和药物耐药性的产生：来自乌干达和南非的嵌套病例对照研究
Anisha Tyagi,Yao Tong,Dustin J Rabideau et al.
Anisha Tyagi et al.
Background: Relationships between distinct antiretroviral therapy (ART) adherence patterns and risk of drug resistance are not well understood. Methods: ...
A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection [0.03%]
GSK3732394治疗HIV-1感染的I期随机对照试验：一种研究性长效生物制剂疗法
Mark Krystal,Shiven Chabria,Daren Austin et al.
Mark Krystal et al.
Background: The GSK3732394 multivalent protein was developed as a novel, long-acting, antiretroviral biologic treatment regimen with three independent, non-cross-resistant mechanisms for inhibiting HIV-1 entry. ...
Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor [0.03%]
抗逆转录病毒治疗使与AIDS相关的肝脏Epstein-Barr病毒感染平滑肌瘤代谢完全缓解
Takahide Ara,Tomoyuki Endo,Hideki Goto et al.
Takahide Ara et al.
Epstein-Barr virus-associated smooth muscle tumor (EBV-SMT) is a rare mesenchymal tumor which occurs in immunocompromised patients. The immune status is an important factor in the treatment of EBV-SMTs, but the efficacy of antiretroviral th...